Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06700083
PHASE1

A Safety, Tolerability, Pharmacokinetic Study of SHR-6934 Injection in Healthy Subjects

Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

View on ClinicalTrials.gov

Summary

This study was a randomized, double-blind, single-dose and multi-dose, placebo-controlled phase Ⅰ clinical trial. Six dose groups were planned for the SAD part of the study and four dose groups were planned for the MAD part. A total of 88 healthy subjects were included.

Official title: Safety, Tolerability, and Pharmacokinetics of Single and Multiple Subcutaneous Injections of SHR-6934 in Healthy Subjects: a Randomized, Double-blind, Dose-escalation, Placebo-controlled Phase I Trial

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

88

Start Date

2024-11

Completion Date

2025-08

Last Updated

2024-11-21

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

SHR-6934 injection

SHR-6934 injection

DRUG

SHR-6934 placebo

SHR-6934 placebo

Locations (1)

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China